Results 61 to 70 of about 157,671 (305)

IV Thrombolysis Facilitates Interventional Reperfusion in Non‐Cardioembolic but Not Cardioembolic Stroke

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Intravenous thrombolysis (IVT) before thrombectomy for ischemic stroke may alter clot structure and procedural performance. We investigated how IVT relates to thrombectomy metrics across stroke etiologies. Methods We performed a time‐to‐event analysis of consecutive patients with anterior circulation large vessel occlusion (acLVO ...
Annahita Sedghi, Daniel P. O. Kaiser, Martin Arndt, Norma J. Diel, Erik Simon, Witold H. Polanski, Volker Puetz, Hagen B. Huttner, Timo Siepmann   +8 more
wiley   +1 more source

Пресс-релиз компании AstraZeneca

Клиническая онкогематология, 2021
Таргетная монотерапия препаратом Калквенс® (акалабрутиниб) рекомендована Национальным институтом здравоохранения и совершенствования медицинской помощи Великобритании (NICE) для пациентов с хроническим лимфоцитарным лейкозом.
doaj   +1 more source

Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets

BMC Cancer, 2022
Background DNA repair deficiencies are characteristic of cancer and homologous recombination deficiency (HRD) is the most common. HRD sensitizes tumour cells to PARP inhibitors so it is important to understand the landscape of HRD across different solid ...
Zhongwu Lai, Matthew Brosnan, Ethan S. Sokol, Mingchao Xie, Jonathan R. Dry, Elizabeth A. Harrington, J. Carl Barrett, Darren Hodgson   +7 more
doaj   +1 more source

Goal Congruence -The Experience of a Performance Management System -A Case Study of AstraZeneca [PDF]

, 2012
Background and discussion: It can be stated that organizations use management control systems in order to influence employees’ behavior in the right direction, with the aim of achieving organizational goals.
Kronberg, Ida, Gustafsson, Maria
core  

Comprehensive Assessment of Arterial, Tissue, and Venous Collaterals for Evaluating the Infarct Growth Rate: The Multimodal Collateral Score

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Collaterals are crucial factors that influence the infarct growth rate (IGR). We aimed to determine whether a comprehensive multimodal collateral score (MCS), incorporating collateral assessment at the arterial, tissue, and venous levels, is associated with functional independence and provides incremental prognostic value over ...
Giorgio Busto, Umberto Pensato, Ilaria Casetta, Giorgio U. Marcello, Angelo Barra, Anna Poggesi, Edoardo Carlesi, Sara Mancini, Andrea Ginestroni, Vittorio Miele, Alessandro Padovani, Andrea Morotti, Enrico Fainardi   +12 more
wiley   +1 more source

Anti‐CD19 CAR T Cells in Autoimmune Encephalitis: Inflammation Controlled, Neurodegeneration Unchecked?

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Just recently, successful chimeric antigen receptor (CAR) T cell therapy was reported in the first patient with refractory, anti‐diacylglycerol lipase alpha (DAGLA) antibody‐mediated autoimmune encephalitis, achieving partial clinical remission.
Dimitrios Mougiakakos, Marwa Al‐Dubai, Denise Walther, Dominic Borie, Jan D. Lünemann, Marc Pawlitzki, Sven G. Meuth, Solveig Henneicke, Stefan Vielhaber, Stefanie Schreiber   +9 more
wiley   +1 more source

"Astrazeneca going beyond - reshaping the blockbuster business model"

, 2021
AstraZeneca (AZN) is a global, science-led biopharmaceutical company focused on on the discovery, development, and commercialisation drugs, primarily for the treatment of diseases in three main areas Oncology, Cardiovascular, Respiratory ...
Revalska, Petya Sergeeva
core  

Efficacy of Inebilizumab in N‐MOmentum Trial Participants With or Without Prior Immunosuppressants

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT This post hoc analysis examined the impact of prior immunosuppressants on the long‐term efficacy and safety of inebilizumab, a cluster of differentiation 19+ B‐cell–depleting monoclonal antibody, in participants with aquaporin‐4–seropositive neuromyelitis optica spectrum disorder from the N‐MOmentum trial (NTC02200770).
Bruce A. C. Cree, Beatrice Suero, Sarah Walsh, Romain Marignier, John W. Lindsey, Ho Jin Kim, Dewei She, Daniel Cimbora, Dustin Cavida, Friedemann Paul   +9 more
wiley   +1 more source

Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy

Communications Biology, 2021
Claire Patterson et al. present the design and development of AZD0466, a drug-dendrimer conjugate, and use preclinical and mathematical models to determine the optimal release rate of the drug from the dendrimer carrier for maximal therapeutic index in ...
Claire M. Patterson, Srividya B. Balachander, Iain Grant, Petar Pop-Damkov, Brian Kelly, William McCoull, Jeremy Parker, Michael Giannis, Kathryn J. Hill, Francis D. Gibbons, Edward J. Hennessy, Paul Kemmitt, Alexander R. Harmer, Sonya Gales, Stuart Purbrick, Sean Redmond, Matthew Skinner, Lorraine Graham, J. Paul Secrist, Alwin G. Schuller, Shenghua Wen, Ammar Adam, Corinne Reimer, Justin Cidado, Martin Wild, Eric Gangl, Stephen E. Fawell, Jamal Saeh, Barry R. Davies, David J. Owen, Marianne B. Ashford   +30 more
doaj   +1 more source

Thromboembolism and the Oxford-AstraZeneca vaccine [PDF]

BMJ, 2021
Perera, R, Fletcher, J
openaire   +2 more sources